VaxInnate’s prototype flu vaccine named as Top 10 Infectious Diseases Projects to Watch in 2011

VaxInnate Corporation announced today that VAX125, its investigational prototype vaccine for seasonal flu, has been named one of the Top 10 Infectious Diseases Projects to Watch in 2011 by Elsevier Business Intelligence and the Windhover Conferences.

“Elsevier Business Intelligence and the Windhover Conferences are respected for their savvy understanding of the biopharmaceutical industry, which makes their selection of VAX125 as a Top 10 project particularly gratifying”

VAX125 was selected by an expert panel based on the vaccine's potential to meet unmet medical needs, as well as its strong science, market potential, and opportunities for partnering.

Robert Becker, PhD, Vice President of Business Development, will make a presentation about VAX125 during Windhover's Therapeutic Area Partnerships conference in Boston on Nov. 3^rd.

"Elsevier Business Intelligence and the Windhover Conferences are respected for their savvy understanding of the biopharmaceutical industry, which makes their selection of VAX125 as a Top 10 project particularly gratifying," said Thomas Hofstaetter, PhD, President and CEO of VaxInnate. "We look forward to discussing VAX125 and the data supporting its potential to improve public health this week in Boston."

Source: VaxInnate Corporation